Hepatocellular carcinoma (HCC) is usually connected with high mortality and the current therapy for advanced HCC, Sorafenib, offers limited survival benefits. cells (Mo-MDSC) was also decreased suggesting the reversion of the immunosuppressive growth microenvironment. Our data exhibited that the combinatorial therapy with poly-ICLC XE169 and Sorafenib enhances growth control and regional immune system response therefore… Continue reading Hepatocellular carcinoma (HCC) is usually connected with high mortality and the